Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | M6223 |
Synonyms | |
Therapy Description |
M6223 targets and binds to TIGIT on immune cells, including tumor-infiltrating lymphocytes, and prevents its interaction with CD112 and CD155, thereby leading to enhanced interaction of CD112 and CD155 with CD226 expressed on natural killer and CD8 T+ cells, which may lead to the activation of anti-tumor immune responses (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
M6223 | M-6223|M 6223 | M6223 targets and binds to TIGIT on immune cells, including tumor-infiltrating lymphocytes, and prevents its interaction with CD112 and CD155, thereby leading to enhanced interaction of CD112 and CD155 with CD226 expressed on natural killer and CD8 T+ cells, which may lead to the activation of anti-tumor immune responses (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04457778 | Phase I | M6223 Bintrafusp alfa + M6223 | First in Human Study of M6223 in Participants With Metastatic or Locally Advanced Solid Unresectable Tumors | Completed | USA | CAN | 0 |